Jefferies lifts target for ImmunityBio stock to USD 14.00

Published on 10/15/2026 at 21:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

In the second quarter of 2026, revenue reached USD 50.70 million, up 92.00 percent. ImmunityBio stock costs EUR 8.89 on October 15, 2026 at 9:21 p.m. CEST.

Analyst targets and upcoming dates

Jefferies lifted its ImmunityBio target to USD 14.00 on October 14, 2026.
Second-quarter revenue reached USD 50.70 million, up 92.00 percent in 2026.
ImmunityBio stock costs EUR 8.89 at Lang & Schwarz on October 15, 2026 at 9:21 p.m. CEST.
ESMO is scheduled for October 23 to October 27, 2026.

IBRX, US45256X1037, Illustration mit AI erstellt.

ImmunityBio (ISIN US45256X1037) saw Jefferies raise its price target from USD 12.00 to USD 14.00 on October 14, 2026, implying 40.85 percent above the Nasdaq price of USD 9.94. Markets Insider reported that the firm kept its Buy rating. At Lang & Schwarz, the stock was trading at EUR 8.89 on October 15, 2026 at 9:21 p.m. CEST.

Revenue reached USD 50.70 million

ImmunityBio reported second-quarter 2026 net product revenue of USD 50.70 million, up 92.00 percent from the year-ago quarter. First-half 2026 revenue reached USD 94.80 million, an increase of 121.00 percent year over year, according to ImmunityBio. The revenue trend gives the analyst target a commercial measure beyond the regulatory story.

The 52-week range spans USD 1.95 to USD 12.43

The Nasdaq price of USD 9.94 on October 15, 2026 stood 20.03 percent below the 52-week high of USD 12.43 and 409.74 percent above the low of USD 1.95. Trading volume was 16,565,599 shares, compared with an average of 10,813,348 shares. On October 14, 2026, ImmunityBio had announced expanded FDA approval for ANKTIVA plus BCG in papillary-only bladder cancer, according to the StockTitan filing page.

Valuation and upcoming dates

ImmunityBio had a market capitalization of USD 10.5 billion and a negative price-to-earnings ratio of -10.23 as of October 15, 2026. The next listed company event is ESMO from October 23 to October 27, 2026, followed by the Society for Neuro-Oncology meeting from November 4 to November 8, 2026, according to ImmunityBio.

Comparison with peers

IBRX (Nasdaq, USD): P/E -10.23, market capitalization USD 10.5 billion

Immunocore (Nasdaq, USD): plus 3.93 percent, P/E -154.57, market capitalization USD 1.5 billion

Summit Therapeutics (Nasdaq, USD): plus 1.29 percent, P/E -13.68, market capitalization USD 12.2 billion

Price at Lang & Schwarz

The euro quotation provides the German investor view, while the Nasdaq figures frame the home-market valuation and range. The next scheduled events may provide further updates on clinical and commercial progress.

At Lang & Schwarz, ImmunityBio was trading at EUR 8.89 on October 15, 2026 at 9:21 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of ImmunityBio stock.